Current pharmacotherapy for Parkinson's disease (PD) is palliative. There is no treatment proven unequivocally to arrest or slow progression of PD. The NINDS Exploratory Trials in Parkinson's Disease (NET-PD) consortium was initiated to conduct clinical research trials of promising agents that could slow the clinical progression of PD. The clinical investigators and staff at the University of Michigan Health System have been involved as a NET-PD site since the inception of NET-PD and have been active participants in all clinical trials conducted by the NET-PD group. Our site has an excellent subject recruitment and retention record. Our site is committed to the safe conduct of clinical trials and has several measures in place to ensure participant safety. We actively participated in the original FS-1 and FS-TOO futility studies. We then enrolled 37 subjects in the LS-1 creatine study and are currently conducting follow-up visits on 33 subjects (retention rate 89%). We are committed to retaining and following these 33 subjects through completion of the LS-1 trial. We are also in the process of enrolling subjects for the FS-ZONE study, which is investigating whether pioglitazone can slow down the clinical progression of PD and have enrolled 2 subjects to date. Additionally, we have strong ties with the Michigan Parkinson Foundation (MPF), the major lay organization for PD in Michigan and plan on implementing a new initiative to increase and retain minority enrollment. Based on our previous experience in NET-PD, our clinical research infrastructure, and connection with the local PD community, we at the University of Michigan believe that we are well-equipped to continue serving as a clinical center for the remaining NET-PD trials. We plan on continuing to cooperate with other NET-PD centers, including the Coordination and Statistical Centers towards the goal of completing the current trials (LS-1 and FS-ZONE).
PD is a slowly progressive, neurodegenerative disorder that causes significant disability and decreased quality of life. Unfortunately, no current therapies or treatment strategies have been proven to slow clinical decline in PD. By taking part in the NET-PD consortium, we will determine if medications such as creatine (LS-1) or pioglitazone (FS-ZONE) can truly slow down the clinical progression of PD. If so, then it will revolutionize the way we treat PD, ultimately resulting in less disability and increased quality of life.
|Chou, Kelvin L; Elm, Jordan J; Wielinski, Catherine L et al. (2017) Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. J Neurol Sci 377:137-143|
|Chou, Kelvin L; Kotagal, Vikas; Bohnen, Nicolaas I (2016) Neuroimaging and clinical predictors of fatigue in Parkinson disease. Parkinsonism Relat Disord 23:45-9|
|Friedman, Joseph H; Beck, James C; Chou, Kelvin L et al. (2016) Fatigue in Parkinson's disease: report from a mutidisciplinary symposium. NPJ Parkinsons Dis 2:|
|Wills, Anne-Marie A; Pérez, Adriana; Wang, Jue et al. (2016) Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease: Secondary Analysis of Longitudinal Data From NINDS Exploratory Trials in Parkinson Disease Long-term Study 1 JAMA Neurol 73:321-8|
|Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators; Kieburtz, Karl; Tilley, Barbara C et al. (2015) Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA 313:584-93|
|Soileau, Michael J; Persad, Carol; Taylor, Jennifer et al. (2014) Caregiver burden in patients with Parkinson disease undergoing deep brain stimulation: an exploratory analysis. J Parkinsons Dis 4:517-21|
|Coleman, Robert R; Kotagal, Vikas; Patil, Parag G et al. (2014) Validity and Efficacy of Screening Algorithms for Assessing Deep Brain Stimulation Candidacy in Parkinson Disease. Mov Disord Clin Pract 1:342-347|
|Chou, Kelvin L; Lenhart, Adrienne; Koeppe, Robert A et al. (2014) Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: cognitive and neurochemical correlates. Parkinsonism Relat Disord 20:1076-80|
|Weathers, Shiao-Pei S; Kotagal, Vikas; Bohnen, Nicolaas I et al. (2014) Risky driving and pedunculopontine nucleus-thalamic cholinergic denervation in Parkinson disease. Parkinsonism Relat Disord 20:13-6|
|Armstrong, Melissa J; Duff-Canning, Sarah; Tang-Wai, David F et al. (2013) The meaning of a ""hippo"" response on the Montreal Cognitive Assessment in Parkinson's disease. Parkinsonism Relat Disord 19:463-5|
Showing the most recent 10 out of 17 publications